ImmuCell Stock

ImmuCell Rule of 40

The Rule of 40 of ImmuCell (ICCC) as of Aug 14, 2026 is 10.31 %. In the previous year, Rule of 40 was 45.39 % — a change of -77.28% (lower).

Rule of 40

10.31 %

YoY

-77.28%

Last updated:

Rule of 40 of ImmuCell is 2026 10.31 % . Rule of 40 of ImmuCell was 2025 45.39 % . It decreases by -77.28% lower compared to the previous year.
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Rule of 40 of ImmuCell is 10.31 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 ImmuCell since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

Quality — ImmuCell

All Key Metrics — ImmuCell